UNASSIGNED: The expression of @entity7596 , @entity68980 in @entity356 is known to be associated with clinical outcome. However, few studies have investigated the role of @entity23363 and @entity8761 ( @entity8761 ) in @entity356 . Therefore, this study assessed the clinical significance of @entity23363 and @entity8761 expression in @entity356 . A total of 39 @entity356 @entity1 received either radical total or distal gastrectomy in this study. Surgical tissue slides were stained with @entity8761 and @entity23363 antibodies, and immunohistochemistry scores and disease-free survival (DFS) rates were analyzed. Among the 19 @entity1 with @entity5 -recurrent or distant @entity3 , 16 were recorded as exhibiting low expression of @entity23363 . The remaining three @entity1 exhibited high expression of the antibody. The results of @entity1 with a higher T stage, N stage and @entity5 grade were less favorable. For @entity1 with @entity420 , the percentage of tissue slides stained with @entity23363 was significantly higher than for those with normal stomach epithelia. The DFS rates of @entity1 with low expression of @entity23363 were significantly associated with poorer DFS rates. In conclusion, high expression of @entity23363 is a favorable prognostic factor in treating @entity1 with @entity420 .

Increased XXXX expression as a favorable prognostic factor in treating @entity356 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity8761 :: ('1025', 'Gene') :: ['cyclin-dependent kinase 9', 'CDK9'] @entity23363 :: ('904', 'Gene') :: ['cyclin T1'] @entity68980 :: ('27241;25802', 'Gene') :: ['B1, D1 and E'] @entity7596 :: ('890', 'Gene') :: ['cyclin A'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity420 :: ('MESH:D000230', 'Disease') :: ['stomach adenocarcinoma', 'adenocarcinoma'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric adenocarcinoma']
@entity23363 :: (904,Gene) :: ['cyclin T1']
